Analysts/Institutional Investor Meet/Con. Call Updates

August 10, 2026 National Stock Exchange of India Limited, BSE Limited, Compliance Department, Compliance Department, Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers, Bandra (East), Mumbai - 400051, Dalal Street, Mumbai - 400001, Maharashtra, India Maharashtra, India Subject : Transcript of the Earnings Call held with Analysts/Investors on August 07, 2026 to discuss the Unaudited Financial Results of the Company for the quarter ended June 30, 2026 Stock Code : BSE – 539787, NSE – HCG Reference : Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir/Madam, Please see attached herewith the Transcript of the Earnings Call held on August 07, 2026, with Analysts/Investors to discuss the Unaudited Financial Results (both Standalone & Consolidated) of the Company for the quarter ended June 30, 2026. This is also available on the website of the Company - https://www.hcgoncology.com/investor- relations/ Kindly take the intimation on record. Thanking you, For HealthCare Global Enterprises Limited Sunu Manuel Company Secretary & Compliance Officer Encl:a/a HealthCare Global Enterprises Limited Reg Off: HCG Towers #8, P. Kalinga Rao Road, Sampangi Ram Nagar, Bengaluru - 560 027 Corp Off: #3, G-Floor, Tower Block, Unity Buildings Complex, Mission Road, Bengaluru - 560 027, Karnataka, India 91 80 4660 7700 | Email-query@hcgel.com | Website - www.hcgoncology.com | CIN: L15200KA1998PLC023489 Ahmedabad | Bengaluru | Bhavnagar | Chennai | Cuttack | Hubballi | Indore | Jaipur | Kalaburagi | Kenya | Kolkata | Mumbai | Nagpur | Nashik | Ongole | Rajkot | Ranchi | Shimoga | Vadodara | Vijayawada | Vizag Healthcare Global Enterprises Limited Q1 FY27 Earnings Conference Call August 07, 2026 Moderator: Ladies and gentlemen, good day, and welcome to the HealthCare Global Enterprises Limited Q1 FY27 Earnings Conference Call. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during this conference call, please signal an operator by pressing star then zero on your touchtone phone. Please note that this conference is being recorded. I now hand the conference over to Mr. Suraj Digawalekar from CDR India. Thank you, and over to you, sir. Suraj Digawalekar: Thank you, Sagar. Good afternoon, everyone, and thank you for joining us on HealthCare Global Enterprises Q1 FY27 Earnings Conference Call. We have with us Dr. Manish Mattoo, Executive Director and CEO; Mr. Sanjeev Kumar, Chief Financial Officer; and Mr. Ravi Gothwal, Head of Investor Relations. We would like to begin the call with opening remarks from the management, following which we will have the forum open for an interactive Q&A session. Before we start, I would like to point out that some statements made in today's discussion may be forward-looking in nature, and a disclaimer to this effect has been included in the earnings presentation shared with you earlier. I would now like to invite Dr. Manish to make his opening remarks. Manish Mattoo: Good afternoon, everyone, and thank you for joining us for HCG's Q1 FY27 earnings call. Before I begin, I would like to warmly welcome our new Chief Financial Officer, Mr. Sanjeev Kumar, who has recently joined HCG. Sanjeev brings more than 3 decades of experience across finance, strategy and business transformation, and I am delighted to have him as part of our leadership team. His experience will further strengthen our execution capabilities as we continue to build India's leading oncology platform. As we enter FY27, our focus has progressed from laying the foundation to executing our strategy and delivering consistent operational and financial performance. Over the past years, we have achieved several important strategic milestones that strengthened our position as India's leading oncology platform. We sharpened our strategic focus through the successful divestment of our Fertility business, which was completed at the end of June '26. We also strengthened our balance sheet through a successful rights issue, expanded our leadership team, successfully commissioned our North Bangalore hospital and continue to advance our brownfield expansion Page 1 of 13 pipeline and other growth initiatives. With these foundational initiatives in place, our priorities are clear: delivering sustainable, profitable growth, driving operational excellence, improving asset utilization, enhancing patient experience, building our clinical differentiation, optimizing our revenue mix while reinforcing our leadership in cancer care. I am pleased to share that we have started FY27 on a strong note. During the quarter, HCG delivered revenue of INR6,951 million, representing approximately 13% year-on-year growth. Our newly operational North Bangalore hospital, which commenced operations in May '26, contributed INR67 million during this very first quarter. More importantly, growth was broad-based with 16 out of our 25 centers, excluding North Bangalore, delivering their highest ever quarterly revenues, reflecting sustained patient demand and improving execution across our hospitals. Revenue growth during the quarter was primarily driven by an 11% increase in patient volumes. ARPP grew by 2%. ARPP improvement driven by favourable payor mix, partly offset by changes in case mix, including a lower contribution from high-value low-margin therapies. Our objective is not to only grow faster, but to grow with a better quality of earnings by treating more complex oncology cases, improving our patient mix, enhancing productivity and generating stronger returns on the capital we deploy. We believe this disciplined approach will create sustainable value for both our patients and our shareholders over the long term. I am encouraged to see the strategy translating into visible outcomes. During the quarter, non-institutional business revenue grew by 17% year-on-year. As a result, our payor mix improved with non-institutional contribution increasing from 67% in Q1 FY'26 to 69% in Q1 FY27. This gradual improvement in revenue mix is an important driver of sustainable profitability and strengthens the long-term quality of our earnings. On the profitability front, reported EBITDA for the quarter stood at INR1,223 million, excluding losses from North Bangalore and one-off costs. Adjusted EBITDA increased by 20% year-on-year to INR1,339 million, with EBITDA margins improving to 19.4% from 18.2% in Q1 FY26. This demonstrates that the underlying operational performance of the business continues to strengthen. Overall, our Q1 performance reflects healthy operating momentum across the network, supported by robust patient demand, improving operational execution and continued progress in enhancing our revenue mix. Let me now briefly touch upon the performance across our operating clusters. The South cluster delivered another strong quarter with revenue growing approximately 16% year-on-year, supported by healthy growth in both patient volumes and realizations. We also witnessed continued improvement in the cash and TPA mix across the Bangalore Center of Excellence and the Vizag cluster. As a reminder, the South cluster numbers include the newly commissioned North Bangalore hospital, which contributed INR67 million of revenue. The West cluster reported a growth of 9%, led by the Maharashtra region, which grew by over 14%, while growth in the Gujarat remained relatively moderate during the quarter. Overall growth was led by volumes, which grew 11% year-on-year and ARPP remained broadly stable during the quarter. The benefits of an improving payor mix were largely offset by changes in case and service mix, including a higher share of medical oncology patient footfalls, which typically carry a lower average revenue per patient. Page 2 of 13 Furthermore, institutional business in West cluster declined by more than 4% year-on- [Showing first 8,000 characters — download PDF for full document]